Abstracts tagged "Biomarkers"

Abstract Number: 2082 • 2013 ACR/ARHP Annual Meeting
Interferon-Regulated Chemokine and Innate Cytokine Scores Identify Refractory Myositis Patients That Respond Better To Rtuximab Therapy
Consuelo Lopez de Padilla¹, Cynthia S. Crowson², Molly S. Hein³, Helen Khun², Rohit Aggarwal⁴, Marc C. Levesque⁵, Dana P. Ascherman⁶, Chester V. Oddis⁷ and Ann M. Reed³, ¹Rheumatology/Immunology Research, Mayo Clinic, Rochester, MN, ²Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ³Rheumatology, Mayo Clinic, Rochester, MN, ⁴Medicine / Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁵Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁶Medicine/Rheumatology, University of Miami, Miami, FL, ⁷Rheum/Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Serum cytokines play an important role in the pathogenesis of myositis by initiating and perpetuating various cellular and humoral autoimmune processes. The aim of…
Abstract Number: 1572 • 2013 ACR/ARHP Annual Meeting
High Type I Interferon In Systemic Lupus Erythematosus Plasma Predicts Future Renal Disease
Kyriakos A. Kirou¹, Mikhail Olferiev¹, Elzbieta E. Jacek¹, Mari Lliguicota¹, Margaret Robotham¹, Wei-Ti Huang², Elena Gkrouzman¹ and Mary K. Crow³, ¹Hospital for Special Surgery, New York, NY, ²Biostatistics, Hospital for Special Surgery, New York, NY, ³Department of Medicine, Hospital for Special Surgery, New York, NY
Background/Purpose: Type I interferon (IFN-I) is elevated in many patients with SLE and is associated with more severe disease. However, the relationship between elevated levels…
Abstract Number: 813 • 2013 ACR/ARHP Annual Meeting
Citrulline Specific CD4+ T Cells Exhibit a Th1 Memory Phenotype In Rheumatoid Arthritis Subjects and Their Ex Vivo Frequency Is Influenced By Both Disease Duration and Biologic Therapy
Eddie James¹, Mary Rieck², Jennifer Pieper³, John Gebe⁴, Betty Yue⁴, Megan Tatum⁵, Charlotta Sandin⁶, Lars Klareskog⁷, Vivianne Malmström⁸ and Jane Buckner⁹, ¹Benaroya Research Institute, Seattle, WA, ²Translational Research Program, Benaroya Research Institute, Seattle, WA, ³Department of Medicine, Karolinska Institutet, Rheumatology Unit, Stockholm, Sweden, ⁴Diabetes Research Program, Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁵Translational Research Program, Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁶Department of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, ⁷Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ⁸Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ⁹Translational Research Program, Benaroya Research Institute, Seattle, WA 98101, USA,, Seattle, WA
Background/Purpose: Rheumatoid arthritis is thought to be a T cell mediated disease, based on its strong association with HLA class II alleles, clinical responsiveness to…
Abstract Number: 2756 • 2013 ACR/ARHP Annual Meeting
Serum Periostin Is Associated With Prevalent Knee Osteoarthritis and Predicts Disease Progression In Women: The Ofely Study
Jean-Charles Rousseau¹, Elisabeth Sornay-Rendu¹, Cindy Bertholon¹, Patrick Garnero² and Roland Chapurlat³, ¹INSERM UMR 1033, Lyon, France, ²INSERM, UMR 1033, Lyon and Cisbio Bioassays, Bagnols/Cèze, France, ³Service de Rhumatologie et Pathologie Osseuse, INSERM UMR 1033 and Université de Lyon, Hôpital Edouard Herriot, Lyon, France
Background/Purpose: Periostin (POSTN) is a secreted vitamin K-dependent (Gla-containing) protein produced by osteoblasts and chondrocytes. The aim of this study was to investigate the relationships…
Abstract Number: 2057 • 2013 ACR/ARHP Annual Meeting
Biomarker and Serologic Predictors Of Clinical Improvement After B Cell Depletion In Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM) – The RIM (Rituximab in Myositis) Trial
Ann M. Reed¹, Cynthia S. Crowson², Molly S. Hein¹, Consuelo Lopez de Padilla³, Helen Khun², Rohit Aggarwal⁴, Dana P. Ascherman⁵, Marc C. Levesque⁶ and Chester V. Oddis⁷, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ³Division of Rheumatology, Mayo Clinic, Rochester, MN, ⁴Medicine / Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁵Medicine/Rheumatology, University of Miami Miller School of Medicine, Miami, FL, ⁶Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁷Rheum/Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: The aim of this study was to examine the longitudinal utility of a biomarker signature in conjunction with myositis autoantibodies (autoAbs) as biomarkers of…
Abstract Number: 1453 • 2013 ACR/ARHP Annual Meeting
Repeated High Or Low Multi-Biomarker Disease Activity (VECTRA^® DA Algorithm) Scores Associated With Radiographic Outcomes In Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor Inhibitors
Shintaro Hirata¹, Wanying Li², Nadine A. Defranoux², Rebecca Bolce², Eric H. Sasso², Satoshi Kubo¹, Shunsuke Fukuyo¹, Kentaro Hanami³, Kunihiro Yamaoka¹, Kazuyoshi Saito¹ and Yoshiya Tanaka¹, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²Crescendo Bioscience Inc., South San Francisco, CA, ³The first department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan
Background/Purpose: A novel multi-biomarker disease activity (MBDA) score that is based on the serum concentrations of 12 biomarkers has been shown to correlate with clinical…
Abstract Number: 651 • 2013 ACR/ARHP Annual Meeting
Growth Differentation Factor-15, a Marker Of lung disease In Systemic Sclerosis, Is Involved In Fibrosis Development But Does Not Impair Fibrosis Development
Stijn Lambrecht¹, Vanessa Smith², Katelijne De wilde³, Julie Coudenys⁴, Filip De Keyser² and Dirk Elewaut⁵, ¹Dept of Rheumatology, Laboratory for Molecular Immunology and Inflammation, Ghent University, Ghent, Belgium, ²Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, ³Deptartment of Rheumatology, Ghent University, Ghent, Belgium, ⁴Dept of Rheumatology, Ghent University, Ghent, Belgium, ⁵Rheumatology, Department of Rheumatology Ghent University Hospital, Ghent, Belgium
Background/Purpose: It is generally known that members of the TGF-β superfamily are involved in the regulation of connective tissue biology in systemic sclerosis (SSc). Growth…
Abstract Number: 2251 • 2012 ACR/ARHP Annual Meeting
High Sensitivity C-Reactive Protein, Disease Activity and Cardiovascular Risk Factors in Systemic Lupus Erythematosus
Chi Chiu Mok¹, Daniel Birmingham², Ling Yin Ho¹ and Brad H. Rovin³, ¹Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong, ²Medicine, Ohio State University Medical Center, Columbus, OH, ³Division of Nephrology, Ohio State University Medical Center, Columbus, OH

Background/Purpose: To study the level of high-sensitivity C-reactive protein (hsCRP) and its relationship with disease activity, damage and cardiovascular risk factors in patients with systemic…
Abstract Number: 1471 • 2012 ACR/ARHP Annual Meeting
Differential Expression of Hepatocyte Growth Factor (HGF) in Patients with Systemic Sclerosis-Associated Pulmonary Arterial Hypertension
Lorinda Chung¹, Catriona Cramb², William H. Robinson³, Virginia D. Steen⁴ and Roham T. Zamanian⁵, ¹Rheumatology, Stanford Univ Medical Center, Palo Alto, CA, ²VA Palo Alto Heatlh Care System and Stanford University, Palo Alto, CA, ³Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ⁴Department of Rheumatology, Georgetown University Medical Center, Washington, DC, ⁵Stanford University, Palo Alto, CA
Background/Purpose: Pulmonary arterial hypertension (PAH) is one of the leading causes of death in patients with systemic sclerosis (SSc). Non-invasive biomarkers are needed to identify…
Abstract Number: 839 • 2012 ACR/ARHP Annual Meeting
Urinary Levels of High Mobility Group Box 1 Protein Are Elevated in Patients with Active Lupus Nephritis, and Correlate with Renal Histopathology
Irene Blanco¹, Neelakshi Jog², Chaim Putterman³, Iris Lee⁴ and Roberto Caricchio⁵, ¹Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ²Rheumatology, Temple University, Philadelphia, PA, ³Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ⁴Nephrology, Temple University, Philadelphia, PA, ⁵Medicine/Rheumatology, Temple University, Philadelphia, PA
Background/Purpose: High mobility group box 1 protein (HMGB-1) had been implicated in the pathogenesis of SLE and potentially lupus nephritis (LN). There is increased expression…
Abstract Number: 560 • 2012 ACR/ARHP Annual Meeting
Proteomic Profiling of Synovial Fluid Reveals Candidate Psoriatic Arthritis Biomarkers
Daniela Cretu¹, Ihor Batruch², Punit Saraon³, Dafna D. Gladman⁴, Fawnda Pellett⁵, Eleftherios Diamandis⁶ and Vinod Chandran⁷, ¹Department of Laboratory Medicine and Pathobiology, University of Toronto, Department of Laboratory Medicine and Pathobiology, Toronto, ON, Canada, ²Department of Pathology and Lab Medicine,, Mount Sinai Hospital, Toronto, ON, Canada, ³Department of Pathology and Lab Medicine, Mount Sinai Hospital, Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada, ⁴Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ⁵Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁶Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada, ⁷Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) is a unique form of arthritis occurring in 30% of psoriasis patients. There is a high prevalence of undiagnosed PsA in…
Abstract Number: 2261 • 2012 ACR/ARHP Annual Meeting
Ovarian Reserve Markers in Reproductive Age Women with Systemic Lupus Erythematosus
Olívio B. Malheiro¹, Carolina P. Rezende¹, Gilda A. Ferreira² and Fernando M. Reis¹, ¹Obstetrics and Gynecology, Federal University of Minas Gerais, Belo Horizonte, Brazil, ²Locomotor System Medicine, Federal University of Minas Gerais, Belo Horizonte, Brazil
Background/Purpose: Systemic lupus erythematosus (SLE) is a multisystem disease, which affects mostly women at reproductive age, and can promote premature ovarian dysfunction related to factors…
Abstract Number: 1473 • 2012 ACR/ARHP Annual Meeting
Sub-Analysis of ELF Score Biomarkers Components Indicates a Specific Correlation with Different Organ Involvement in Systemic Sclerosis
Giuseppina Abignano¹, Giovanna Cuomo², Maya H. Buch³, William M. Rosenberg⁴, Gabriele Valentini⁵, Paul Emery⁶ and Francesco Del Galdo⁷, ¹Chapel Allerton Hospital Leeds Insitute of Molecular medicine, Division of Rheumatic and Musculoskeletal Disease, University of Leeds, Leeds Institute of Molecular Medicine and LMBRU, Leeds, United Kingdom, ²Department of Internal and Experimental Medicine, Second University of Naples, Naples, Italy, ³Division of Rheumatic and Musculoskeletal Disease, University of Leeds, Leeds Institute of Molecular Medicine and LMBRU, Leeds, United Kingdom, ⁴Centre for Hepatology - UCL, London, United Kingdom, ⁵Rheumatology/Int Med, Second University of Naples, Rheumatology Unit, Naples, Italy, ⁶Division of Rheumatic and Musculoskeletal Disease, University of Leeds, Leeds Institute of Molecular Medicine and NIHR LMBRU, Leeds, United Kingdom, ⁷Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Background/Purpose: A recent large multicenter study has identified an algorithm, known as Enhanced Liver Fibrosis (ELF), by combining the serum concentrations of amino-terminal propeptide of procollagen type III (PIIINP),…
Abstract Number: 840 • 2012 ACR/ARHP Annual Meeting
Do Serum Hepcidin 25 Levels Predict SLE Renal or Non-Renal Flares?
Alexandra Friedman¹, Nicholas Young², Paul Jensen³, Xiaolin Zhang⁴, Wael N. Jarjour⁵, Brad H. Rovin⁴, Daniel Birmingham³, Lee Hebert³ and Stacy P. Ardoin⁶, ¹Immunology and Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH, ²Immunology and Rheumatology, The Ohio State University Medical Center, Columbus, OH, ³Medicine, Ohio State University Medical Center, Columbus, OH, ⁴Division of Nephrology, Ohio State University Medical Center, Columbus, OH, ⁵Dept of Rheumatology/Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, ⁶Pediatric & Adult Rheumatology, Ohio State University College of Medicine, Columbus, OH
Background/Purpose: Biomarkers are needed which can accurately predict systemic lupus erythematosus (SLE) flare, allowing tailoring of immunosuppressive therapy to minimize disease damage and medication toxicity.…
Abstract Number: 568 • 2012 ACR/ARHP Annual Meeting
14-3-3 Eta Is a Modifiable Serum Biomarker That Marks Adalimumab Response in Psoriatic Arthritis
Anthony Marotta¹, A. W van Kuijk², Walter P. Maksymowych³ and Paul Peter Tak⁴, ¹Augurex Life Sciences Corp, North Vancouver, BC, Canada, ²Clinical Immunology / Rheumatology, Academic Medical Centre/University of Amsterdam, Amsterdam, Netherlands, ³Department of Medicine, University of Alberta, Edmonton, AB, Canada, ⁴Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands
Background/Purpose: 14-3-3 eta is a synovial-derived biomarker whose serum expression is independently associated with joint damage in RA and PsA. We previously reported that 14-3-3…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].